ABCB1 and malignant colon neoplasm: Other TKIs targeting the ErbB receptor family, specifically allitinib, dacomitinib, vandetanib and AZ5104, did not sensitize cells to paclitaxel treatment in our model despite previous reports of ABCB1 inhibition by dacomitinib in colon cancer cell lines (Fig 3A) [54].